Resmed Inc. (RMD)

Name: Resmed Inc. (RMD): results, filings decoded, planned insider sales, 13F holders, insiders, Congress and short interest
Creator: GreekSoup
License: https://creativecommons.org/licenses/by/4.0/

Compare with another name

Resmed Inc. (RMD) reported revenue of $1.5 billion for Q4 FY2026, the quarter ended 30 June 2026, up 8.6% on the same quarter a year earlier. Net income was $383 million, up 1.0% on the year, and diluted earnings per share $2.64. The figures are the company's own, from the 10-K it filed with the SEC on 13 August 2026.

Revenue$1.5 billionup 8.6%

Net income$383 millionup 1.0%

Diluted EPS$2.64

QuarterQ4 FY2026ended 30 June 2026

Ratios

From the filings

ROE23.1%

ROCE26.0%

Operating margin33.4%

Net margin26.9%

FCF margin29.2%

Interest covern/a

Debt to equity0.10

Cash conversion1.19

Share count, 1 year-1.5%

Sales CAGR, 3 years10.2%

Profit CAGR, 3 years19.3%

EPS, TTM$10.43

At the close of 21 September 2026

Price$223.61

Market cap$32.3 billion

Stock P/E21.44

Price to book4.90

EV / EBITDA15.06

Dividend yield1.1%

Market cap / sales5.71

52-week high$283.28

52-week low$182.82

Price, 1 year-18.1%

Price CAGR, 3 years17.9%

Price CAGR, 5 years-5.0%

Every figure is arithmetic on the filed lines (hover a name for the formula); the priced ones use the latest daily close, CBOE delayed quotes, daily history, by CBOE, for splits. Debt to equity here stands on the total debt Resmed Inc. states in its own filing, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.

Price, 17 September 2021 to 21 September 2026

Show

50-day average 200-day average Volume

Daily closes from CBOE delayed quotes, daily history, by CBOE, for splits; the last is 21 September 2026. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Drawn in your browser; the range and overlay you pick are remembered here only.

The public record on RMD

Filings	19 in twelve months: 9 current reports (8-K), about 5 other events; 5 results of operations; 3 officer or director change; 2 regulation fd disclosure; 1 change of auditor
Planned insider sales	35 Form 144 notices in twelve months, $27.3 million; latest 8 September 2026
Options tape	put/call 0.61 by open interest on 23 September 2026; the straddle prices a 6.0% move to 16 October 2026
Holders	9 of the followed funds hold it; largest Geode Capital Management; 5 Schedule 13D or 13G filings in twelve months
Insider trading	33 sales and 0 purchases on Form 4 in twelve months
Congress	0 House trades disclosed in six months
Short interest	13.1 million shares short, 8.94 days to cover at 31 August 2026
Documents	the 10-K, the 10-Qs, the proxy and 5 earnings press releases, each linked

Quarterly results, the last 12 quarters

	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026	Q3 FY2026	Q4 FY2026 *
Revenue	1,102	1,163	1,197	1,223	1,225	1,282	1,292	1,348	1,336	1,423	1,431	1,464
Cost of revenue	502	516	504	508	507	531	525	528	515	544	540	602
Gross profit	600	647	693	716	717	751	766	820	821	879	891	861
Gross margin	54%	56%	58%	58%	59%	59%	59%	61%	61%	62%	62%	59%
R&D	75.7	73.9	77.1	80.9	79.5	81.4	83.9	86.4	87.3	91.0	94.3	106
SG&A	223	222	230	242	239	242	245	265	259	278	286	296
Operating income	289	275	375	381	387	417	426	455	447	492	500	449
Operating margin	26%	24%	31%	31%	32%	33%	33%	34%	33%	35%	35%	31%
Pre-tax income	272	259	375	358	383	418	418	458	447	496	502	474
Tax rate	19%	20%	20%	18%	19%	18%	13%	17%	22%	21%	21%	19%
Net income	219	209	300	292	311	345	365	380	349	393	399	383
Net margin	20%	18%	25%	24%	25%	27%	28%	28%	26%	28%	28%	26%
Diluted EPS	$1.49	$1.42	$2.04	$1.97	$2.11	$2.34	$2.48	$2.58	$2.37	$2.68	$2.74	$2.64
Operating cash flow	286	273	402	440	326	309	579	539	457	340	554	455
Capital expenditure	30.0	23.4	21.2	24.9	17.8	20.6	20.8	30.6	43.0	28.5	33.7	51.1
Free cash flow	256	249	381	415	308	288	558	508	414	311	520	404
Buybacks	0.0	50.0	50.0	50.0	50.0	75.0	75.0	100	150	175	175	200
Dividends paid	70.6	70.7	70.5	70.6	77.9	77.7	77.7	77.6	87.8	87.6	87.2	87.1
Shares outstanding	147m	147m	147m	147m	147m	147m	147m	146m	146m	146m	145m	144m
Filing	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Profit and loss, 12 fiscal years and the trailing twelve months

	FY2015	FY2016	FY2017	FY2018 †	FY2019 †	FY2020	FY2021	FY2022 †	FY2023	FY2024	FY2025 †	FY2026	TTM
Revenue	1,679	1,839	2,067	2,340	2,607	2,957	3,197	3,578	4,223	4,685	5,146	5,653	5,653
Cost of revenue	668	772	865	1,005	1,113	1,239	1,358	1,554	1,867	2,030	2,091	2,202	2,202
Gross profit	1,011	1,066	1,202	1,335	1,494	1,718	1,839	2,024	2,356	2,655	3,055	3,452	3,452
Gross margin	60.2%	58.0%	58.1%	57.0%	57.3%	58.1%	57.5%	56.6%	55.8%	56.7%	59.4%	61.1%	61.1%
Research and development	115	119	144	155	181	202	225	254	288	308	331	378	378
Selling, general and administrative	479	488	554	600	645	677	670	738	874	917	993	1,120	1,120
Operating income	409	429	426	542	579	810	904	1,000	1,132	1,320	1,685	1,887	1,887
Operating margin	24.4%	23.3%	20.6%	23.2%	22.2%	27.4%	28.3%	28.0%	26.8%	28.2%	32.7%	33.4%	33.4%
Interest expense	5.8	11.2	28.2	28.4	36.2	40.4	24.0	n/a	n/a	n/a	n/a	n/a	n/a
Pre-tax income	436	440	419	521	519	733	884	960	1,102	1,265	1,678	1,919	1,919
Income tax	83.0	87.2	76.5	206	114	111	409	181	204	244	277	396	396
Effective tax rate	19.0%	19.8%	18.3%	39.5%	22.0%	15.2%	46.3%	18.8%	18.5%	19.3%	16.5%	20.6%	20.6%
Net income	353	352	342	316	405	622	475	779	898	1,021	1,401	1,523	1,523
Net margin	21.0%	19.2%	16.6%	13.5%	15.5%	21.0%	14.8%	21.8%	21.3%	21.8%	27.2%	26.9%	26.9%
Diluted EPS	$2.47	$2.49	$2.40	$2.19	$2.80	$4.27	$3.24	$5.30	$6.09	$6.92	$9.51	$10.43	$10.43
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

Income statement lines from each year's 10-K, the year linked to its filing; TTM is the sum of the last four quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Cash flow and capital returned

	FY2015	FY2016	FY2017	FY2018 †	FY2019 †	FY2020	FY2021	FY2022 †	FY2023	FY2024	FY2025 †	FY2026	TTM
Operating cash flow	n/a	548	414	505	459	802	737	351	693	1,401	1,752	1,806	1,806
Capital expenditure	62.5	58.5	62.2	62.6	68.7	95.3	103	135	120	99.5	89.9	156	156
Free cash flow	n/a	489	352	442	390	707	634	216	574	1,302	1,662	1,650	1,650
Free cash flow margin	n/a	26.6%	17.0%	18.9%	15.0%	23.9%	19.8%	6.0%	13.6%	27.8%	32.3%	29.2%	29.2%
Depreciation and amortisation	73.1	86.8	112	120	151	155	157	160	165	177	198	201	201
Share-based compensation	47.9	46.4	45.9	48.4	52.1	57.6	63.9	65.3	71.1	80.2	91.7	104	104
Buybacks	160	102	n/a	53.8	22.8	n/a	n/a	0.0	0.0	150	300	700	700
Dividends paid	157	168	186	199	212	225	227	245	258	282	311	350	350
Dividend per share	$1.12	$1.20	$1.32	$1.40	$1.48	$1.56	$1.56	$1.68	$1.76	$1.92	$2.12	$2.40	n/a
Diluted shares, weighted	143m	142m	142m	144m	144m	146m	146m	147m	147m	148m	147m	146m	146m
Shares outstanding at period end	140m	141m	142m	143m	144m	145m	146m	146m	147m	147m	146m	144m	144m
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

Buybacks and dividends are the cash paid in the year, from the cash flow statement; the dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet at year end

	FY2015	FY2016	FY2017	FY2018 †	FY2019 †	FY2020	FY2021	FY2022 †	FY2023	FY2024	FY2025 †	FY2026	TTM
Total assets	2,184	3,259	3,468	3,064	4,108	4,587	4,728	5,096	6,752	6,872	8,174	8,966	8,966
Cash and equivalents	717	731	822	189	147	463	295	274	228	238	1,209	1,469	1,469
Receivables	363	382	451	484	528	475	614	576	705	837	939	1,036	1,036
Inventory	247	224	268	269	350	417	457	744	998	822	928	946	946
Goodwill	264	1,059	1,065	1,069	1,856	1,890	1,928	1,936	2,770	2,842	3,047	2,910	2,910
Total debt, as filed	301	1,175	1,079	281	1,271	1,176	655	775	1,441	707	668	659	659
Long-term debt	301	875	1,079	270	1,259	1,164	643	765	1,431	697	658	399	399
Borrowings, as the company tags them	n/a	875	1,080	272	1,262	1,168	646	770	1,435	700	660	400	400
Operating lease liabilities	n/a	n/a	n/a	n/a	n/a	102	115	120	117	141	153	137	137
Shareholders' equity	1,587	1,695	1,960	2,059	2,072	2,497	2,886	3,361	4,130	4,864	5,968	6,585	6,585
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

At the fiscal year end; the TTM column is the latest quarter end. A line the company does not tag under the usual name is left out.

Compounded growth

	10 years	5 years	3 years	TTM
Sales growth, compounded	11.9%	12.1%	10.2%	9.9%
Profit growth, compounded	15.8%	26.3%	19.3%	8.8%
Return on equity, average	20.6%	22.5%	22.5%	23.1%

Compounded growth is the latest fiscal year over the year that many years earlier, annualised; the TTM column is the last four quarters over the four before. Return on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Peers: Surgical & Medical Instruments & Apparatus

Company	Market cap	P/E	ROE	Op. margin	Sales growth TTM	Debt to equity	Div. yield
Stryker Corp. SYK	$105.2 billion	28.41	15.5%	21.4%	8.5%	0.62	1.3%
3M Co. MMM	$85.1 billion	29.30	101.5%	18.4%	2.3%	3.69	1.8%
Boston Scientific Corp. BSX	$63.4 billion	17.70	14.7%	19.8%	13.5%	0.44	n/a
Becton Dickinson & Co. BDX	$49.2 billion	54.59	3.9%	9.6%	-2.6%	0.55	2.3%
Dexcom Inc. DXCM	$33.7 billion	35.38	38.1%	22.9%	15.5%	0.03	n/a
Resmed Inc. RMD	$32.3 billion	21.44	23.1%	33.4%	9.9%	0.10	1.1%
West Pharmaceutical Services Inc. WST	$25.5 billion	46.32	18.9%	20.5%	12.4%	0.07	0.2%
Solventum Corp. SOLV	$15.1 billion	10.85	29.9%	25.0%	-0.9%	1.06	n/a
Baxter International Inc. BAX	$11.9 billion	n/a	-17.1%	-2.4%	5.4%	1.54	2.3%
Insulet Corp. PODD	$9.7 billion	26.37	26.4%	16.9%	29.4%	0.65	n/a

The names on this site in the same industry (the SEC's SIC description), by market capitalisation. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close.

Filings

Filing	Period	Filed	Where
10-K	30 June 2026	13 August 2026	EDGAR
10-Q	31 March 2026	1 May 2026	EDGAR
10-Q	31 December 2025	30 January 2026	EDGAR
10-Q	30 September 2025	31 October 2025	EDGAR
10-K	30 June 2025	8 August 2025	EDGAR
10-Q	31 March 2025	24 April 2025	EDGAR
10-Q	31 December 2024	31 January 2025	EDGAR
10-Q	30 September 2024	25 October 2024	EDGAR
10-K	30 June 2024	9 August 2024	EDGAR
10-Q	31 March 2024	26 April 2024	EDGAR

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install